|Day Low/High||1.71 / 1.93|
|52 Wk Low/High||0.88 / 2.95|
Research Spotlights OncoSec's Next Generation Electroporation (EP) Platform
Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse® IL-12 in combination with KEYTRUDA® (pembrolizumab)
Small-caps are lagging and breadth is negative, but the computer algorithms are very impressive.
OncoSec's Polycistronic Interleukin-12 Immune Modulator (PIIM) DNA Plasmid Vector Enables Simultaneous Delivery of Multiple Complementary Anti-Cancer Agents
Updated Phase 2 Efficacy and Durability Findings to Be Presented at the 2017 Society for Immunotherapy of Cancer Annual Meeting
Mr. O'Connor's appointment effective immediately; former President and CEO of Advaxis and Senior Vice President of ImClone Systems
OncoSec presented at the 2nd Annual Biomarkers & Precision Medicine USA Congress
Additional abstract highlighting preclinical data from OncoSec's novel multi-gene expression platform
Enrolling patients with unresectable metastatic melanoma who have progressed or are progressing on an anti-PD-1 therapy
Former President and CEO of Advaxis Immunotherapies and Senior Vice President of ImClone Systems adds significant biopharma clinical, regulatory, business development, and fundraising expertise to OncoSec
Former Head of Global Research and Development for Merck Serono and Head of Global Medical Affairs of Bristol-Myers Squibb brings biopharma drug development, fundraising and M&A experience to OncoSec
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.